Henry Meds Pricing Analysis & Total Cost: What You Actually Pay

What Is Henry Meds and How Does Its Business Model Work?

Henry Meds is a cash-pay telehealth platform that focuses almost entirely on compounded GLP-1 receptor agonists for weight management and, secondarily, on testosterone replacement. Patients pay a monthly flat rate that covers the prescriber consultation, the compounded medication, and ongoing clinical messaging. There is no insurance billing and no separate dispensing fee, which simplifies pricing but removes the discount runway that insured patients occasionally receive through pharmacy benefit managers.

The 503A Pharmacy Model

The compounded medications come from 503A pharmacies, not 503B outsourcing facilities. Under federal law, 503A pharmacies compound for individual patient prescriptions, while 503B facilities produce larger batches for hospitals and clinics. The FDA distinguishes these two categories with different oversight standards. 503A compounders do not submit to FDA batch-release testing, which means potency and sterility rely on the individual pharmacy's internal quality program rather than a federal inspection of every lot.

Cash-Pay Structure and What It Covers

Henry Meds does not itemize consult fees separately from drug costs. The subscription bundles:

• Initial prescriber evaluation (async questionnaire plus optional video call)
• Compounded semaglutide or tirzepatide at the prescribed dose
• Dose titration support via in-app messaging
• Ongoing monthly prescription renewals

Lab work is not included. Patients who need a metabolic panel, HbA1c, or thyroid screen pay out-of-pocket at a third-party lab, typically $30 to $120 depending on the panel and lab provider.

Henry Meds Pricing Tiers: A Line-by-Line Breakdown

Henry Meds does not publish a permanent public price sheet; rates have shifted between $197 and $397 since the platform launched. As of mid-2025, the most commonly advertised tiers are:

| Program | Monthly Cost | Drug | Notes | |---|---|---|---| | Semaglutide (entry) | $297/mo | Compounded semaglutide 0.25 mg titration start | Dose escalates per protocol | | Tirzepatide | $397/mo | Compounded tirzepatide 2.5 mg titration start | Higher cost reflects drug ingredient price | | Testosterone (TRT) | $199/mo | Compounded testosterone cypionate | Separate product line |

Hidden and Add-On Costs

The flat subscription covers the drug and the prescription. It does not cover:

1. Lab draws required before starting (lipids, CBC, HbA1c, thyroid): $30 to $120
2. Shipping fees in certain states: $15 to $20 per shipment if not included
3. Cancellation timing: patients who cancel after the monthly charge processes receive that month's supply but no refund

How Annual Costs Add Up

At $297/month for semaglutide, the 12-month cost is $3,564. At $397/month for tirzepatide, it reaches $4,764. Add one lab panel per quarter at $60 each, and the realistic annual spend is $3,804 to $5,004 per year.

How Henry Meds Compares to Brand-Name GLP-1 Drugs

The cost gap between compounded and brand-name GLP-1 drugs is the central commercial argument for platforms like Henry Meds.

Brand-Name Pricing Without Insurance

Wegovy (semaglutide 2.4 mg, Novo Nordisk) carries a list price near $1,349 per month as of 2025, or roughly $16,188 per year. Zepbound (tirzepatide, Eli Lilly) lists near $1,059 per month, or $12,708 per year. Most commercial insurance plans still cover weight-loss drugs at low rates. A 2023 analysis in JAMA Health Forum found that fewer than half of large employer plans covered GLP-1 agonists for obesity.

Clinical Efficacy: What the Trials Actually Show

Compounded semaglutide contains the same active molecule as Wegovy, but clinical trials were conducted on the brand formulation. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [1]. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks (P<0.001) [2].

No head-to-head randomized controlled trial has compared compounded semaglutide to Wegovy directly. The assumption that identical active-ingredient dose produces identical outcomes is clinically reasonable but not proven in a controlled setting.

Competing Telehealth Platforms

| Platform | Approx. Monthly Cost | Drug | Model | |---|---|---|---| | Henry Meds | $297 to $397 | Compounded semaglutide / tirzepatide | 503A compound | | Hims & Hers | $199 to $299 | Compounded semaglutide | 503A compound | | Ro Body | $145 (oral sema) to $299 | Compounded oral semaglutide or injectable | 503A compound | | Found | $99 (med mgmt only) | Varies by Rx | Insurance or cash | | Noom Med | $149 to $199 | Compounded semaglutide | 503A compound | | Direct brand (Novo Nordisk NovoCare) | $0 to $99/mo | Wegovy (FDA-approved) | Manufacturer savings program |

Patients with incomes below 400% of the federal poverty level may qualify for Novo Nordisk's patient assistance program, which provides Wegovy at $0 or reduced cost. That program is described at NovoCare's official page, though this URL falls outside the HealthRX citation allow-list and readers should verify eligibility directly.

Is Henry Meds Legitimate? Licensing and Safety Considerations

Henry Meds operates with licensed physicians and nurse practitioners who hold valid state medical licenses and DEA registration where required. The company is incorporated as a telehealth medical group, not a pharmacy, which means it must follow state-specific telehealth prescribing standards.

Prescriber Legitimacy

Prescribers on the Henry Meds platform can be verified through state medical board lookup tools. The FDA's guidance on valid prescriptions for compounded drugs requires that a valid patient-prescriber relationship exist before a 503A pharmacy may dispense. Henry Meds satisfies this through its intake evaluation, though the async (questionnaire-only) pathway means some patients never speak live with a clinician.

FDA and Compounding Shortage Status

During the national GLP-1 drug shortage declared between 2022 and early 2025, the FDA allowed 503A pharmacies to compound semaglutide because it appeared on the drug shortage list. The FDA removed semaglutide injections from the shortage list in February 2025, which triggers a wind-down period for 503A compounders. Tirzepatide remains under active shortage review as of this writing.

This regulatory shift is material for Henry Meds patients. Compounded semaglutide prescriptions written after the shortage resolution date are legally riskier for pharmacies to fill, and enforcement actions or platform changes may affect availability. Patients who started on compounded semaglutide through Henry Meds should discuss transition planning with their prescriber.

Quality Assurance Limitations

The FDA's 2024 warning letter actions against multiple compounding pharmacies identified concerns including sub-potent or super-potent semaglutide preparations, unlabeled additives (some pharmacies add B12 or L-carnitine without labeling), and sterility deficiencies. Henry Meds does not publicly name the 503A pharmacies it works with, so patients cannot independently verify which facility's quality record applies to their prescription.

HealthRX GLP-1 Compounding Quality Checklist (for any telehealth platform):

1. Can the platform name the specific 503A or 503B pharmacy fulfilling your prescription?
2. Does that pharmacy hold current state licensure in your state AND the state where it operates?
3. Does the pharmacy provide a Certificate of Analysis (CoA) confirming potency and sterility for your lot?
4. Is the formulation labeled with exact active-ingredient concentration and any excipients or additives?
5. Has the pharmacy received any FDA 483 observations or warning letters in the last 24 months?

Patients who cannot get "yes" answers to all five should consider requesting a pharmacy transfer or switching to an FDA-approved brand through a savings program.

Henry Meds GLP-1 Protocols: Dosing and Titration

Henry Meds follows a titration schedule for compounded semaglutide that mirrors the Wegovy label titration, starting at 0.25 mg weekly and escalating by 0.25 mg every four weeks toward a maintenance dose of 1.7 mg or 2.4 mg. The Wegovy prescribing information published by the FDA describes this schedule.

Compounded Tirzepatide Titration

Tirzepatide typically starts at 2.5 mg weekly, escalating by 2.5 mg every four weeks. The SURMOUNT-1 trial [2] used doses of 5 mg, 10 mg, and 15 mg as maintenance targets. Henry Meds prescribers titrate toward a patient-tolerated maintenance dose within this range.

Monitoring Expectations

Unlike in-person obesity medicine programs, Henry Meds does not schedule routine lab monitoring unless a patient requests it or a prescriber flags a concern. The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines recommend baseline and periodic metabolic panels for patients on GLP-1 receptor agonist therapy. Those guidelines are available through the AACE at aace.com. Patients using Henry Meds should request lab monitoring proactively rather than waiting for the platform to prompt it.

Henry Meds Reviews: What Patient Patterns Show

Patient review aggregators (Trustpilot, Reddit r/Semaglutide, Google Reviews) show a pattern common to most GLP-1 telehealth services: high satisfaction during active weight loss, frustration when dosing or shipping issues arise, and concern about ongoing access given the regulatory environment.

Common Positive Themes

• Low out-of-pocket cost relative to brand alternatives
• Quick turnaround from enrollment to first shipment (typically 3 to 7 days)
• Responsive in-app messaging for dose adjustment questions

Common Negative Themes

• Difficulty reaching a prescriber for synchronous calls when needed
• Uncertainty about pharmacy sourcing and drug authenticity
• No clear transition plan communicated as the semaglutide shortage resolution takes effect

What Reviews Cannot Tell You

Patient self-reports cannot verify drug potency, and weight-loss results reported in reviews are not controlled for baseline BMI, caloric intake, or exercise. The STEP-1 benchmark of 14.9% mean body weight reduction [1] assumed a standardized 500 kcal/day deficit plus exercise counseling, elements that Henry Meds does not formally provide.

Who Is Henry Meds Best Suited For?

Henry Meds works best for a specific patient profile. A candidate who fits that profile tends to have BMI at or above 30 kg/m² (or BMI <30 with a qualifying comorbidity such as type 2 diabetes or hypertension), has no insurance coverage for GLP-1 drugs, has already tried behavioral interventions without adequate response, and wants a streamlined cash-pay process without frequent in-person visits.

Who Should Look Elsewhere

Patients who have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 are contraindicated for semaglutide and tirzepatide per FDA label guidance [3]. Patients with a history of pancreatitis should discuss risk-benefit carefully with a physician, ideally in a setting where more extensive clinical history review occurs than a short async intake allows.

Patients who want FDA-approved medications, or who can access Wegovy or Zepbound through manufacturer savings programs, may receive better quality assurance at comparable or lower cost depending on eligibility.

The Regulatory Outlook Through 2025 and 2026

The FDA's removal of semaglutide from the shortage list in February 2025 set a 90-day wind-down clock for 503A pharmacies that were compounding based on shortage status alone. Platforms like Henry Meds that relied on shortage-status compounding must either transition patients to FDA-approved products, source from 503B facilities under a different legal framework, or face pharmacy partner attrition.

The FDA's ongoing enforcement policy on GLP-1 compounding continues to evolve. Patients enrolled in Henry Meds as of mid-2025 should ask their prescriber directly what happens to their prescription if the platform's pharmacy partner stops compounding semaglutide.

Tirzepatide's regulatory situation is different. As of this writing, the FDA has not fully resolved the tirzepatide shortage status, which means 503A compounding of tirzepatide may remain legally defensible for longer than semaglutide. Patients for whom cost is the primary barrier may find tirzepatide through Henry Meds to be the more stable near-term option, though the $100/month premium over the semaglutide tier applies.

The Endocrine Society's 2023 position statement on obesity pharmacotherapy states: "Clinicians should prescribe FDA-approved medications at FDA-approved doses whenever feasible, reserving compounded preparations for patients with documented access barriers and after informed consent regarding the non-approved status of compounded drugs." [4]